Amgen announced it is investing more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, CA. The biotech company has been in Thousand Oaks since 1980. "At Amgen, we're continuing to invest in the future of American science and innovation," said Robert A. Bradway, chairman and chief executive officer at Amgen. The new center for science and innovation enhances the company's global network of sites, leveraging decades of operational expertise and technological advancements. Related:Merck Nixes Planned London R&D Center